Le Ray Emmanuelle, Jagannath Sundar, Palumbo Antonio
a Hematology Department , CHU Cochin, Paris V René Descartes University , Paris , France.
b Tisch Cancer Institute/Multiple Myeloma Program , Mount Sinai Medical Center , New York , NY , USA.
Expert Rev Hematol. 2016 Jan;9(1):91-105. doi: 10.1586/17474086.2016.1119041.
The development of proteasome inhibitors (PIs) and immunomodulatory drugs has significantly improved outcomes for patients with relapsed/refractory multiple myeloma (RRMM); however, not all patients benefit from treatment with these agents and some patients can become drug refractory over time. Due to the largely incurable nature of multiple myeloma, the development of newer agents is ongoing and includes new oral PIs (ixazomib), immunotherapies (e.g., CD38- or SLAMF7-targeted antibodies), and small molecules. This review provides an overview of the advances in targeted therapy for patients with RRMM, including recently approved agents, with a focus on monotherapy and combined targeted therapies.
蛋白酶体抑制剂（PIs）和免疫调节药物的研发显著改善了复发/难治性多发性骨髓瘤（RRMM）患者的治疗结局；然而，并非所有患者都能从这些药物治疗中获益，而且一些患者可能会随着时间推移而产生耐药性。由于多发性骨髓瘤在很大程度上无法治愈，新型药物的研发仍在进行中，包括新型口服蛋白酶体抑制剂（伊沙佐米）、免疫疗法（如靶向CD38或信号淋巴细胞激活分子家族成员7的抗体）以及小分子药物。本文综述了RRMM患者靶向治疗的进展，包括近期获批的药物，重点介绍了单药治疗和联合靶向治疗。
